GlassScriptPhysician profile
Jacqueline Watts
NPI 1497379770
$21,831.16
in general payments reported to CMS, 2019-2025
27 companies · $4,153 in 2025
The $4,153 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,610 · 2022: $3,414 · 2023: $6,836 · 2024: $4,818 · 2025: $4,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $736 · Education: $422 · Travel and Lodging: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,277.07 |
| Consulting Fee | $736.00 |
| Education | $421.92 |
| Travel and Lodging | $371.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,188.06 | 2022-2025 | Sotyktu, Cobenfy |
| Abbvie INC. | $3,104.64 | 2021-2025 | |
| Leo Pharma INC. | $2,820.06 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $1,879.51 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Incyte Corporation | $1,693.19 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $1,074.01 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $989.26 | 2021-2025 | |
| Genzyme Corporation | $961.11 | 2021-2025 | |
| Ucb, INC. | $874.43 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $837.57 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $829.05 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $810.37 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $667.05 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $568.20 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $498.20 | 2021-2025 | Dupixent, Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $256.40 | 2023-2025 | Vtama, Hadlima |
| Biofrontera INC. | $190.81 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $141.56 | 2021-2023 | Otezla |
| Botanix Sb INC | $119.94 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.57 | 2023-2024 | Spevigo, Cyltezo |
| Fresenius Kabi USA, LLC | $30.84 | 2025 | Tyenne |
| Lnhc, INC | $24.76 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $21.10 | 2023 | Poteligeo |
| Dermira, INC. | $21.08 | 2021 | |
| Sandoz INC. | $19.32 | 2023 | Hyrimoz |
| Verrica Pharmaceuticals INC. | $13.08 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.